ORKA
Oruka Therapeutics Inc.
$30.18
-$0.03(-0.10%)
60
Overall
60
Value
66
Tech
55
Quality
Market Cap
$1.49B
Volume
697.84K
52W Range
$5.49 - $32.28
Target Price
$46.90
Company Overview
| Mkt Cap | $1.49B | Price | $30.18 |
| Volume | 697.84K | Change | -0.10% |
| P/E Ratio | -279.2 | Open | $30.07 |
| Revenue | -- | Prev Close | $30.21 |
| Net Income | $-5.3M | 52W Range | $5.49 - $32.28 |
| Div Yield | N/A | Target | $46.90 |
| Overall | 60 | Value | 60 |
| Quality | 55 | Technical | 66 |
No chart data available
About Oruka Therapeutics Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest News
Oruka Therapeutics Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORKA | $30.18 | -0.1% | 697.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |